OBJECTIVES: To evaluate the cost-effectiveness (CE) immunization with 13-Valent Pneumococcal Conjugate Vaccine (PCV13) compared with no vaccination and also comparing with PCV10, considering direct effects in the Brazilian private market. METHODS: A decision tree model was used to estimate the total number of disease and disease sequels caused by S. pneumoniae and the clinical outcomes were mortality and incidence rates. The vaccination coverage rate was 90% considering a four-dose schedule,  the pneumococcal disease according to the Brazilian label and the target population was a hypothetical birth cohort in Brazil followed 5 years from the Brazilian Private Market Healthcare System perspective. RESULTS: Considering only direct costs and benefits, the program with PCV13 comparing with PCV10 will avoid 60.652 cases of disease including pneumonia and invasive disease, and also 133.615 saved life years. At a current vaccination’s price (PCV13 cost of R$ 198,11 and PCV10 R$ 150,90) the CE results will be R$ 3.976,00 for life years gained and R$ 8.760,00 for disease averted. Considering the same price for PCV13 and PCV10, PCV13 will achieve cost-saving results. The program with PCV13 comparing with no vaccination will avoid 204.507 cases of disease including AOM, pneumonia and invasive disease, and also 162.239 saved life years. The CE results will be R$ 13.974,00 for life years gained and R$ 11.086,00 for disease adverted. CONCLUSIONS: The analysis suggests that the PCV13 within the Brazilian private market expected to be very cost-effective relative to PCV10 and to no vaccination. Considering the same price, PCV13 comparing to PCV10 may result in reduction of mortality with resultant cost savings (R$ 35 Million).